Session: 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster III
Hematology Disease Topics & Pathways:
Research, Clinical Research, Real-world evidence
Results: The study included 56 ENKTL patients. Of these, 34 (60.7%) underwent autologous HSCT, and 22 (39.2%) underwent allogeneic HSCT, with 4, 3, and 15 patients receiving sibling, unrelated donor, and haploidentical transplants, respectively. The allo-HSCT patients demonstrated a higher percentage of disease progression (95% vs. 62%, P=0.004), bone marrow invasion (40.9% vs. 5.9%, P=0.002), and pre-transplantation non-complete remission (CR) status (45.4% vs. 11.8%, P=0.009), with no significant differences in other clinical characteristics between the groups. Non-relapse mortality(NRM)was higher in the allo-HSCT group (31.8% vs. 0%, P<0.001), and the 3-year CIR was 27.4% for auto-HSCT and 9% for allo-HSCT (P=0.0499). There was a statistically significant difference in OS (3-year OS: 92% for auto-HSCT and 59% for allo-HSCT, P=0.002) but not in PFS (3-year PFS: 73% for auto-HSCT and 59% for allo-HSCT, P=0.29) between the auto-HSCT and allo-HSCT groups. There was a significant difference in OS and PFS between patients with CR and non-CR pre-transplantation disease status, with 3-year OS of 89% for CR and 50% for non-CR, and 3-year PFS of 76% for CR and 43% for non-CR (P<0.001 and P=0.009, respectively). Among advanced patients in CR post-transplantation, there were 18 in the auto-HSCT group and 12 in the allo-HSCT group. There was no significant difference in NRM between auto-HSCT and allo-HSCT (P=0.078), with 1-year NRM of 0% and 16.7%, respectively. The 3-year CIR was significantly different between the two groups (P=0.042), with rates of 26.7% for auto-HSCT and 0% for allo-HSCT. However, OS and PFS were not statistically different between the two groups (P=0.53), with 3-year OS of 85.9% for auto-HSCT and 83.3% for allo-HSCT, and 3-year PFS of 73.3% for auto-HSCT and 83.3% for allo-HSCT.
Conclusion: Pre-transplant lymphoma control is a critical determinant of transplantation outcomes, and achieving CR is an independent beneficial factor for survival. For advanced ENKTL patients achieving CR after chemotherapy, both auto-HSCT and allo-HSCT are effective in improving OS and PFS. Taking into account the costs, adverse effects, and the quality of life post-transplant, autologous transplantation may be a suitable option for patients who have achieved complete remission. Given the limited number of cases, these results await further confirmation with a larger sample.
Disclosures: No relevant conflicts of interest to declare.